Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Eshbal Acquires a 55% Interest in Dare to Be Different Foods (click to learn more) CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Regenicin Inc (EM) RGIN

Healthcare Biotechnology
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of... see more

Current News (EXPM:RGIN)

Regenicin Reports 2016 Operating Results, Outlines Milestones for 2017

PR Newswire January 18, 2017

Regenicin Signs Supplier Agreement with Pure Med Farma LLC to Provide Closed Herd Collagen for the Manufacturing of NovaDerm®

PR Newswire November 17, 2016

Regenicin, Inc. Completes Successful Pre-IND Meeting with Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm®

PR Newswire November 1, 2016

Regenicin, Inc. Announces Scheduled Pre-IND Meeting with U.S. Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm®

PR Newswire October 12, 2016

Regenicin Conducts an Evaluation of its Proprietary Collagen-Based Scaffold for Use in New Autologous Cultured Skin Substitute

PR Newswire October 5, 2016

FDA Grants Orphan-Drug Designation for Regenicin's NovaDerm® Cultured Skin Substitute

PR Newswire August 29, 2016

Regenicin Reports 2015 Operating Results, Outlines Milestones for Q1 2016

PR Newswire February 9, 2016

Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus

PR Newswire March 3, 2015

Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.

PR Newswire November 19, 2014
View More News ››

Opinion & Analysis (EXPM:RGIN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:RGIN)

about Regenicin

7-Jun-11 03:37 pm Regenicin, Inc. is a biotechnology company with corporateheadquarters in Little Falls, New Jersey. The Company...
equityman33 - June 16, 2011

PermaDermâ„¢ technology used on more than 150 pedi

Regenicin, Inc. is currently working with their contract manufacturer toprepare for pre-market approval of PermaDerm™ from the FDA...
equityman33 - June 7, 2011
View more Bullboard ››

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic ...
View More »

Podcasts